Recombinant Human SOCS-3 His-tag Protein, CF

Measured by its binding ability in a functional ELISA. Recombinant Human SOCS‑3 His-tag Protein (Catalog # 11817-S3) binds to Human/Mouse SOCS-3 Antibody (MAB5696) with an ED50 of 0.150-1.50 ng/mL.

2 μg/lane of Recombinant Human SOCS‑3 His-tag Protein (Catalog # 11817-S3) was resolved with SDS-PAGE under reducing (R) condition and visualized by Coomassie® Blue staining, showing bands at 26-31 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human SOCS-3 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Human SOCS‑3 His-tag binds to Human/Mouse SOCS‑3 Antibody (Catalog # MAB5696) with an ED₅₀ of 0.150-1.50 ng/mL.
• Source: E. coli-derived human SOCS-3 protein
  Val2-Leu255, with a C-terminal 6-His tag
• N-terminal Sequence: Val 2
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 25.5 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 26-31 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human SOCS-3 His-tag Protein, CF

• ATOD4
• CIS3
• CIS3CIS-3
• Cish3
• cytokine-induced SH2 protein 3
• Cytokine-inducible SH2 protein 3
• SOCS3
• SOCS-3
• SOCS-3STAT-induced STAT inhibitor 3
• SSI-3
• SSI-3ATOD4
• SSI3MGC71791
• suppressor of cytokine signaling 3

Background

Suppressor of Cytokine Signaling 3 (SOCS-3) is a key intracellular negative‑feedback regulator of cytokine signaling, functioning primarily within the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. SOCS-3 is rapidly induced following cytokine stimulation and acts to constrain the intensity and duration of signaling downstream of multiple inflammatory mediators, particularly those utilizing gp130‑associated receptors, including interleukin‑6 (IL‑6) family cytokines (1, 2). Structurally, SOCS-3 contains an SH2 domain, a C‑terminal SOCS box, and an N‑terminal kinase inhibitory region (KIR). Mechanistic studies have demonstrated that SOCS-3 directly binds to JAK1, JAK2, and TYK2 while simultaneously engaging specific cytokine receptor phosphotyrosine motifs, conferring receptor‑restricted inhibition of JAK catalytic activity. This dual binding explains the selectivity of SOCS-3 for a subset of cytokine receptors, distinguishing it functionally from SOCS-1 (1, 3). SOCS-3 plays a critical role in immune homeostasis and inflammation, where it limits STAT-3‑dependent transcriptional programs and prevents pathological cytokine amplification. Genetic and conditional deletion studies have shown that SOCS-3 is essential for regulating inflammatory responses in myeloid and epithelial compartments, as well as for maintaining balanced signaling downstream of IL‑6, G‑CSF, leptin, and IL‑12 receptors (2, 4). In cancer and chronic inflammatory disease, SOCS-3 exhibits context‑dependent functions. Reduced SOCS-3 expression has been associated with sustained STAT3 activation, tumor‑promoting inflammation, and oncogenic signaling, while elevated SOCS-3 levels can contribute to immune evasion by dampening anti‑tumor cytokine responses. Consequently, SOCS-3 is increasingly recognized both as a disease biomarker and as a potential target for therapeutic modulation in cancer and inflammatory disorders (5, 6). Recombinant human SOCS-3 is therefore a valuable research tool for studying cytokine signal attenuation, JAK/STAT pathway specificity, gp130‑mediated signaling, inflammation, and tumor‑associated immune regulation, as well as for evaluating SOCS‑based therapeutic strategies.

1. Babon, J. J. et al. (2012) Immunity 36:239.
2. Mahony, R. et al. (2016) Cell. Mol. Life Sci. 73:3323.
3. White, C. A. et al. (2013) JAK‑STAT 2:e25045.
4. Carow, B. & Rottenberg, M. E. (2014) Front. Immunol. 5:58.
5. Zhang, Y. et al. (2025) Biol. Proced. Online 27:36.
6. Morelli, M. et al. (2024) Front. Immunol. 15:1393799.